跳转至内容
Merck
CN
所有图片(1)

文件

安全信息

485A-1

Sigma-Aldrich

ATRX Rabbit Polyclonal Antibody

别名:

ATP-dependent helicase ATRX, X-linked helicase II, X-linked nuclear protein (XNP)

登录查看公司和协议定价
所有图片(1)

About This Item

UNSPSC代码:
41116161

生物来源

rabbit blood

质量水平

100
500

偶联物

unconjugated

抗体形式

IgG fraction of antiserum

抗体产品类型

primary antibodies

描述

For In Vitro Diagnostic Use in Select Regions

形式

buffered aqueous solution

种属反应性

human

包装

vial of 0.1 mL (concentrate (485A-14))
vial of 0.1 mL (concentrate (485A-14-RUO) Research Use Only)
vial of 0.5 mL (concentrate (485A-15))
vial of 1.0 mL (concentrate (485A-16))
vial of 1.0 mL (concentrate (485A-16-RUO) Research Use Only)
vial of 1.0 mL (concentrate (485A-17-RUO) Research Use Only)
vial of 1.0 mL (pre-dilute ready-to-use (485A-17))
vial of 7.0 mL (concentrate (485A-18-RUO) Research Use Only)
vial of 7.0 mL (pre-dilute ready-to-use (485A-18))

制造商/商品名称

Cell Marque™

技术

immunocytochemistry: suitable (formalin-fixed, paraffin-embedded sections 1:50-1:50 (concentrated))

同位素/亚型

IgG

控制

astrocytoma, brain, glioblastoma, oligodendroglioma

运输

wet ice

储存温度

2-8°C

可视化

nuclear

一般描述

Diffuse gliomas are classified based on histological and molecular features to achieve an integrated diagnosis. Molecular diagnostic markers include IDH mutation, 1p/19q co-deletion, and TP53 mutation. ATRX is a chromatin remodeling protein and its mutation status may be used as a molecular diagnostic marker within the diff use glioma classification algorithm. Anti-ATRX is used to identify mutant ATRX by a loss of ATRX expression in neoplastic cells when compared with internal positive controls (endothelial cells, glia, and neurons). Grade II/III astrocytoma classification includes IDH mutant, ATRX mutant, and 1p/19q retention, while grade II/III oligodendroglioma includes IDH mutant, ATRX wildtype, and 1p/19q co-deletion; p53 expression may also serve as an aid in diagnosis. ATRX mutation is frequently, but not always, mutually exclusive with 1p/19q co-deletion.

质量

United States - IVD
Canada - RUO
European Union - IVD
Japan - RUO

外形

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide.

制备说明

Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.

其他说明

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

法律信息

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our 产品选型工具.

WGK

WGK 2

法规信息

监管及禁止进口产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Daniel J Brat et al.
The New England journal of medicine, 372(26), 2481-2498 (2015-06-11)
Diffuse low-grade and intermediate-grade gliomas (which together make up the lower-grade gliomas, World Health Organization grades II and III) have highly variable clinical behavior that is not adequately predicted on the basis of histologic class. Some are indolent; others quickly
Masako Ikemura et al.
Histopathology, 69(2), 260-267 (2016-01-08)
We performed an immunohistochemical analysis of alpha-thalassaemia/mental retardation syndrome X-linked (ATRX) expression in adult diffuse gliomas, with reference to clinicopathological and genetic features, to determine the utility of this analysis in diagnostic practice. A total of 193 adult diffuse gliomas
Matthew D Wood et al.
Diagnostic pathology, 14(1), 29-29 (2019-04-11)
Insights into the molecular underpinnings of primary central nervous system tumors have radically changed the approach to tumor diagnosis and classification. Diagnostic emphasis has shifted from the morphology of a tumor under the microscope to an integrated approach based on
Akane Yamamichi et al.
Brain tumor pathology, 35(2), 106-113 (2018-03-20)
The IDH-mutant and 1p/19q co-deletion (1p19q codel) provides significant diagnostic and prognostic value in lower-grade gliomas. As ATRX mutation and 1p19q codel are mutually exclusive, ATRX immunohistochemistry (IHC) may substitute for 1p19q codel, but this has not been comprehensively examined.
David E Reuss et al.
Acta neuropathologica, 129(1), 133-146 (2014-11-28)
Diffuse gliomas are represented in the 2007 WHO classification as astrocytomas, oligoastrocytomas and oligodendrogliomas of grades II and III and glioblastomas WHO grade IV. Molecular data on these tumors have a major impact on prognosis and therapy of the patients.
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门